{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:59:44Z","timestamp":1792432784580,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>With the increasing aging population and progressive nature of the disease, Alzheimer\u2019s disease (AD) poses to be an oncoming epidemic with limited therapeutic strategies. It is characterized by memory loss, behavioral instability, impaired cognitive function, predominantly, cognitive inability manifested due to the accumulation of \u03b2-amyloid, with malfunctioned cholinergic system. Rivastigmine, a reversible dual cholinesterase inhibitor, is a more tolerable and widely used choice of drug for AD. However, rivastigmine being hydrophilic and undergoing the first-pass metabolism exhibits low CNS bioavailability. Nanoformulations including liposomes and PLGA nanoparticles can encapsulate hydrophilic drugs and deliver them efficiently to the brain. Besides, the nasal route is receiving considerable attention recently, due to its direct access to the brain. Therefore, the present study attempts to evaluate the pharmacokinetic and pharmacodynamic properties of nasal liposomal and PLGA nanoparticle formulations of rivastigmine in acute scopolamine-induced amnesia and chronic colchicine induced cognitive dysfunction animal models, and validate the best formulation by employing pharmacokinetic and pharmacodynamic (PK-PD) modeling. Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax\u2009=\u20095\u00a0min), higher Cmax (1489.5\u2009\u00b1\u2009620.71), enhanced systemic bioavailability (<jats:italic>F<\/jats:italic>\u2009=\u2009118.65\u2009\u00b1\u200923.54; AUC\u2009=\u200935,921.75\u2009\u00b1\u20099559.46), increased half-life (30.92\u2009\u00b1\u20098.38\u00a0min), and reduced clearance rate (Kel (1\/min)\u2009=\u20090.0224\u2009\u00b1\u20090.006) compared to oral rivastigmine (Tmax\u2009=\u200915\u00a0min; Cmax\u2009=\u200956.29\u2009\u00b1\u200927.05; <jats:italic>F<\/jats:italic>\u2009=\u20094.39\u2009\u00b1\u20091.82; AUC\u2009=\u20091663.79\u2009\u00b1\u2009813.54; t1\/2\u2009=\u200913.48\u2009\u00b1\u20095.79; Kel (1\/min)\u2009=\u20090.0514\u2009\u00b1\u20090.023). Further, the liposomal formulation significantly rescued the memory deficit induced by scopolamine as well as colchicine superior to other formulations as assessed in Morris water maze and passive avoidance tasks. PK-PD modeling demonstrated a strong correlation between the pharmacokinetic parameters and acetylcholinesterase inhibition of liposomal formulation.<\/jats:p>","DOI":"10.1007\/s00210-021-02096-0","type":"journal-article","created":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T07:03:26Z","timestamp":1622790206000},"page":"1737-1755","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"394","author":[{"given":"Sampath Kumar L.","family":"Rompicherla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Arumugam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree Lalitha","family":"Bojja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Mallikarjuna","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"2096_CR1","doi-asserted-by":"crossref","unstructured":"(2020) 2020 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dementia 16: 391-460","DOI":"10.1002\/alz.12068"},{"key":"2096_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2018.05.011","volume":"281","author":"M Agrawal","year":"2018","unstructured":"Agrawal M et al (2018) Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release 281:139\u2013177","journal-title":"J Control Release"},{"key":"2096_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3109\/03639049709146145","volume":"23","author":"J Akbu\u01e7a","year":"1997","unstructured":"Akbu\u01e7a J, Bergi\u015fadi N (1997) Effect of drug properties on physical and release characteristics of Eudragit microspheres prepared by spherical crystallization technique. Drug Dev Ind Pharm 23:407\u2013411","journal-title":"Drug Dev Ind Pharm"},{"key":"2096_CR4","first-page":"419","volume":"22","author":"LG Apostolova","year":"2016","unstructured":"Apostolova LG (2016) Alzheimer disease. Continuum 22:419\u2013434","journal-title":"Continuum"},{"key":"2096_CR5","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2478\/v10007-008-0014-3","volume":"58","author":"K Arumugam","year":"2008","unstructured":"Arumugam K et al (2008) A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm 58:287\u2013297","journal-title":"Acta Pharm"},{"key":"2096_CR6","first-page":"493","volume":"59","author":"K Arumugam","year":"2009","unstructured":"Arumugam K et al (2009) Gender differences in the pharmacokinetics of rivastigmine in rats. Arzneimittelforschung 59:493\u2013497","journal-title":"Arzneimittelforschung"},{"key":"2096_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/bmc.1455","volume":"25","author":"K Arumugam","year":"2011","unstructured":"Arumugam K et al (2011) Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC-MS\/MS. Biomed Chromatogr 25:353\u2013361","journal-title":"Biomed Chromatogr"},{"key":"2096_CR8","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1039\/C6CS00636A","volume":"46","author":"S Behzadi","year":"2017","unstructured":"Behzadi S et al (2017) Cellular uptake of nanoparticles: Journey inside the cell. Chem Soc Rev 46:4218\u20134244","journal-title":"Chem Soc Rev"},{"key":"2096_CR9","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s00213-018-4866-z","volume":"235","author":"AM Bokare","year":"2018","unstructured":"Bokare AM, Bhonde M, Goel R, Nayak Y (2018) 5-HT6 receptor agonist and antagonist modulates ICV-STZ-induced memory impairment in rats. Psychopharmacology 235:1557\u20131570","journal-title":"Psychopharmacology"},{"key":"2096_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA Deture","year":"2019","unstructured":"Deture MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener 14:1\u201318","journal-title":"Mol Neurodegener"},{"key":"2096_CR11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2165\/11206380-000000000-00000","volume":"71","author":"S Dhillon","year":"2011","unstructured":"Dhillon S (2011) Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimers type. Drugs 71:1209\u20131231","journal-title":"Drugs"},{"key":"2096_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42004-019-0133-4","volume":"2","author":"SN Dighe","year":"2019","unstructured":"Dighe SN et al (2019) Rivastigmine and metabolite analogues with putative Alzheimer\u2019s disease-modifying properties in a Caenorhabditis elegans model. Commun Chem 2:1\u201314","journal-title":"Commun Chem"},{"key":"2096_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/0006-8993(90)91021-8","volume":"517","author":"DF Emerich","year":"1990","unstructured":"Emerich DF, Walsh TJ (1990) Cholinergic cell loss and cognitive impairments following intraventricular or intradentate injection of colchicine. Brain Res 517:157\u2013167","journal-title":"Brain Res"},{"key":"2096_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2018.10.009","volume":"143","author":"F Erd\u0151","year":"2018","unstructured":"Erd\u0151 F, Bors LA, Farkas D, Bajza \u00c1, Gizurarson S (2018) Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 143:155\u2013170","journal-title":"Brain Res Bull"},{"key":"2096_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1248\/cpb.54.156","volume":"54","author":"JY Fang","year":"2006","unstructured":"Fang JY, Chen JP, Leu YL, Wang HY (2006) Characterization and evaluation of silk protein hydrogels for drug delivery. Chem Pharm Bull 54:156\u2013162","journal-title":"Chem Pharm Bull"},{"key":"2096_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin VL et al (2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:459\u2013480","journal-title":"Lancet Neurol"},{"key":"2096_CR17","doi-asserted-by":"crossref","unstructured":"Hong SS, Oh KT, Choi HG, Lim SJ (2019) Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. Pharmaceutics 11(10):540","DOI":"10.3390\/pharmaceutics11100540"},{"key":"2096_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1592\/phco.20.1.1.34664","volume":"20","author":"MW Jann","year":"2000","unstructured":"Jann MW (2000) Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer\u2019s disease. Pharmacotherapy 20:1\u201312","journal-title":"Pharmacotherapy"},{"key":"2096_CR19","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00210-015-1084-7","volume":"388","author":"A Kaur","year":"2015","unstructured":"Kaur A, Bali A, Singh N, Jaggi AS (2015) Investigating the stress attenuating potential of furosemide in immobilization and electric foot-shock stress models in mice. Naunyn Schmiedebergs Arch Pharmacol 388:497\u2013507","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2096_CR20","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2042098617750555","volume":"9","author":"R Khoury","year":"2018","unstructured":"Khoury R, Rajamanickam J, Grossberg GT (2018) An update on the safety of current therapies for Alzheimer\u2019s disease: focus on rivastigmine. Ther Adv Drug Saf 9:171\u2013178","journal-title":"Ther Adv Drug Saf"},{"key":"2096_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jneumeth.2017.05.012","volume":"286","author":"JKS Krishnan","year":"2017","unstructured":"Krishnan JKS et al (2017) Effect of administration method, animal weight and age on the intranasal delivery of drugs to the brain. J Neurosci Methods 286:16\u201321","journal-title":"J Neurosci Methods"},{"key":"2096_CR22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jconrel.2008.10.002","volume":"133","author":"H Li","year":"2009","unstructured":"Li H et al (2009) Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Release 133:238\u2013244","journal-title":"J Control Release"},{"key":"2096_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0091-3057(01)00634-7","volume":"71","author":"T Nakayama","year":"2002","unstructured":"Nakayama T, Sawada T (2002) Involvement of microtubule integrity in memory impairment caused by colchicine. Pharmacol Biochem Behav 71:119\u2013138","journal-title":"Pharmacol Biochem Behav"},{"key":"2096_CR24","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/WNR.0000000000000799","volume":"28","author":"M Nampoothiri","year":"2017","unstructured":"Nampoothiri M et al (2017) Effect of insulin on spatial memory in aluminum chloride-induced dementia in rats. NeuroReport 28:540\u2013544","journal-title":"NeuroReport"},{"key":"2096_CR25","first-page":"1044","volume":"69","author":"M Pohanka","year":"2015","unstructured":"Pohanka M (2015) Determination of acetylcholinesterase and butyrylcholinesterase activity without dilution of biological samples. Chem Pap 69:1044\u20131049","journal-title":"Chem Pap"},{"key":"2096_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.13005\/bpj\/1692","volume":"12","author":"SE Praveenkumar","year":"2019","unstructured":"Praveenkumar SE et al (2019) Amelioration of aluminium chloride (AlCl3) induced neurotoxicity by combination of rivastigmine and memantine with artesunate in Albino Wistar rats. Biomed Pharmacol J 12:703\u2013711","journal-title":"Biomed Pharmacol J"},{"key":"2096_CR27","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i6.10","volume":"26","author":"A Puri","year":"2009","unstructured":"Puri A et al (2009) Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst 26:523\u2013580","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"2096_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3389\/fphar.2015.00286","volume":"6","author":"L Sercombe","year":"2015","unstructured":"Sercombe L et al (2015) Advances and challenges of liposome assisted drug delivery. Front Pharmacol 6:286","journal-title":"Front Pharmacol"},{"key":"2096_CR29","first-page":"1479","volume":"20","author":"K Sharma","year":"2019","unstructured":"Sharma K (2019) Cholinesterase inhibitors as Alzheimer\u2019s therapeutics (Review). Mol Med Rep 20:1479\u20131487","journal-title":"Mol Med Rep"},{"key":"2096_CR30","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.2147\/IJN.S117210","volume":"11","author":"DB Vieira","year":"2016","unstructured":"Vieira DB, Gamarra LF (2016) Getting into the brain: Liposome-based strategies for effective drug delivery across the blood\u2013brain barrier. Int J Nanomed 11:5381\u20135414","journal-title":"Int J Nanomed"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-021-02096-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-021-02096-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-021-02096-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T07:04:44Z","timestamp":1626937484000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-021-02096-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2096"],"URL":"https:\/\/doi.org\/10.1007\/s00210-021-02096-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,4]]},"assertion":[{"value":"2 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experimentation protocol was approved by the Institutional Animal Ethical Committee of Manipal University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}